Multiple Myeloma Clinical Trials in Irvine, California
12 studies are recruiting for multiple myeloma in Irvine, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope - Lennar Foundation Cancer Center, Irvine, California
- Locations
- 34 in total
- Run by
- Genentech, Inc.
-
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-C…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- City of Hope - Lennar Foundation Cancer Center, Irvine, California
- Locations
- 75 in total
- Run by
- Hoffmann-La Roche
-
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California
- Locations
- 270 in total
- Run by
- Janssen Research & Development, LLC
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California
- Locations
- 144 in total
- Run by
- Janssen Research & Development, LLC
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California
- Locations
- 71 in total
- Run by
- Janssen Research & Development, LLC
-
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
- Locations
- 151 in total
- Run by
- Janssen Research & Development, LLC
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Hoag Health Center Irvine, Irvine, California
- Locations
- 270 in total
- Run by
- Pfizer
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Research Site, Irvine, California
- Locations
- 43 in total
- Run by
- AstraZeneca
-
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, to…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine, California
- Locations
- 11 in total
- Run by
- AbbVie
-
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911, Irvine, California
- Locations
- 34 in total
- Run by
- AbbVie
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
- Stage
- Phase 4
- Ages
- 18 and older
- Site
- UCI Health - Irvine Infusion Pharmacy ACC, Irvine, California
- Locations
- 33 in total
- Run by
- Pfizer
-
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- City of Hope at Irvine Lennar, Irvine, California
- Locations
- 11 in total
- Run by
- City of Hope Medical Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.